# Polyrizon Ltd.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Polyrizon Ltd.).

## Overview

Polyrizon Ltd. is a development-stage biotechnology company focused on nasal hydrogel medical-device technologies. Its core platforms are Capture and Contain (C&C), a nasal spray designed to form a barrier in the nasal cavity, and Trap and Target (T&T), an earlier-stage program for intranasal delivery of active pharmaceutical ingredients.

## Products & services

• Capture and Contain (C&C) nasal hydrogel spray
• Hydrogel barrier technology for the nasal cavity
• Intranasal delivery platform for drugs and APIs
• Trap and Target (T&T) pre-clinical nasal delivery program

- **Nasal barrier sprays** (60%) — Hydrogel-based sprays intended to form a containment barrier in the nasal cavity.
- **Intranasal drug-delivery technologies** (30%) — Platforms designed to improve nasal deposition, bioadhesion, and retention for APIs.
- **Pre-clinical R&D programs** (10%) — Earlier-stage development work for new nasal delivery and barrier applications.

- Capture and Contain (C&C) nasal hydrogel spray
- Hydrogel barrier technology for the nasal cavity
- Intranasal delivery platform for drugs and APIs
- Trap and Target (T&T) pre-clinical nasal delivery program

## Customers

Polyrizon’s potential customers include healthcare providers, consumers, and pharmaceutical partners that would use or commercialize nasal spray-based barrier or delivery products. Because the company is in development stage, commercialization appears centered on future licensing, partnering, or regulated product sales rather than broad current market distribution.

- **Healthcare consumers** (primary) — Potential users of nasal barrier sprays designed to reduce contact with viruses and allergens.
- **Pharmaceutical partners** (primary) — Companies that could license or collaborate on intranasal delivery of APIs.
- **Medical device distributors** (secondary) — Channel partners that may commercialize or distribute nasal spray products.
- **Clinical and research collaborators** (secondary) — Institutions supporting pre-clinical testing, formulation work, and validation.

- Healthcare consumers seeking nasal barrier protection
- Patients needing intranasal drug-delivery products
- Pharmaceutical partners for API delivery applications
- Medical device or biotech commercial partners

## Geography

The available reports identify Polyrizon as a United States-based company, while the excerpted filings also reference the company as a foreign private issuer. No country-by-country revenue or operating breakdown is disclosed in the provided material, so the geographic profile cannot be mapped more specifically from these excerpts.

- United States-based company
- Foreign private issuer filing with the SEC
- No country revenue disclosure in provided excerpts
- Geographic exposure likely depends on future commercialization partners

## Strategy

Polyrizon’s strategy is centered on advancing its C&C nasal hydrogel platform and extending the technology into additional intranasal applications. The company also appears focused on building the technical and regulatory foundation needed to support future commercialization, partnering, or clinical development.

- **Advance C&C product development** (short-term) — The core platform is the basis for near-term product and partnering potential.
- **Extend intranasal delivery capabilities** (medium-term) — Improved retention and bioadhesion can broaden medical use cases and licensing value.
- **Develop T&T pre-clinical pipeline** (long-term) — A broader pipeline can support long-term platform value and partnering opportunities.

- Advance the Capture and Contain platform
- Improve bioadhesion and nasal retention
- Develop intranasal API delivery applications
- Progress the earlier-stage Trap and Target program

## Risks

Polyrizon faces the typical risks of a development-stage biotech and medical-device company, including technical, regulatory, and commercialization uncertainty. Its value proposition depends on proving that the hydrogel spray platform is safe, effective, durable, and scalable in real-world use.

- **Regulatory approval risk** [high] — Nasal hydrogel products may require clinical evidence and regulatory clearance before commercialization.
- **Technical efficacy risk** [high] — The platform must demonstrate barrier performance, retention, and safety in the nasal cavity.
- **Commercialization risk** [high] — Market acceptance may depend on pricing, distribution, and partner interest.
- **Funding and dilution risk** [high] — Development-stage biotech businesses often require external capital before revenue generation.

- Clinical or technical failure could limit product feasibility
- Regulatory approvals may be slow or uncertain
- Commercial adoption depends on efficacy and user acceptance
- Development-stage funding needs may remain substantial
- Competing nasal sprays or barrier technologies may emerge

## Accounting

As a development-stage company, Polyrizon’s reported numbers are likely shaped by research and development expense recognition, stock-based compensation, and judgments around whether any capitalized development costs are appropriate. If the company enters collaboration, licensing, or product sales arrangements, revenue recognition timing and deliverable assessment will become important to reported results.

- **Research and development expense** — Major driver of reported loss in development-stage periods
- **Stock-based compensation** — Can materially affect reported expenses and equity
- **Revenue recognition** — May shift reported revenue between periods
- **Development asset impairment** — Could create non-cash write-downs

- R&D expense recognition for pre-clinical development
- Stock-based compensation for executive and employee awards
- Potential revenue recognition for future licensing or product sales
- Possible capitalization and impairment judgments for development assets

---

*Last updated: 2026-09-28T12:13:43.690886+00:00*